The purpose of this study is to see how two doses of Flunisolide HFA (an FDA approved inhaled medication to treat asthma) affect the small airways in children with asthma.

开始日期2015-03-01

申办/合作机构

University of Louisville

[+1]

NCT00346775

/ Completed临床3期

A Randomized, Single-Blind, Cross-Over, Multicenter Study to Validate the Preference Module of the Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q) Administered to Adult Subjects With Seasonal Allergic Rhinitis During a Three-week Cross-over Study

The Protocol section needs to be updated using the following text "The main goal of the study was to validate the Preference Module of the EARNS-Q and to test the reliability using Treatment Satisfaction Questionnaire for Medicines (TSQM), a validated questionnaire for determining satisfaction among different treatment. The EARNS-Q is divided into 2 modules, an Experience Module and a Preference Module. The Experience Module includes 28 items, fourteen attribute rating items followed by fourteen importance weighing questions. The Preference Module includes the same items along with preference questions related to each item as well as a global preference question.

开始日期2006-05-01

申办/合作机构

GSK Plc

NCT00203684

/ Unknown status临床1/2期IIT

The Effects of Different Sized Inhaled Corticosteroids on Peripheral Lung Inflammation in Asthma Assessed Through Lung Tissue Samples (SMART Protocol)

Asthmatics have inflammation in the large airways (tubes through which air travels in and out of the lungs). The large airways are located in the central lung. New research shows that asthmatics also have inflammation in the small airways. The small airways are located in the peripheral lung (the parts of the lung away from the central lung).
Until now, most of the inhaled medications available have been made up of big particles that never reach the peripheral lung. The purpose of this study is to try to measure the level of inflammation in the peripheral lung in asthmatics and see if this inflammation can be decreased with different types of inhaled corticosteroids. The investigators will check airway inflammation before and after use of an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC), and before and after use of an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA).
Subjects will make 6 study visits over two phases of the study. In the first phase, the investigators will collect baseline information about subjects while they are using placebo (inactive substance). In the second phase, subjects will take either the large or small particle corticosteroid.
Visits will involve questionnaires and various tests measuring lung function (such as spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be measured as an indication of inflammation. Subjects will also measure and make note of lung function at home twice daily using a peak expiratory flow meter. Two of the visits will involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue samples without surgery. Another two of the visits will involve the use of high resolution computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the lungs.

开始日期-

申办/合作机构

University of California, Los Angeles

100 项与氟尼缩松相关的临床结果

登录后查看更多信息

100 项与氟尼缩松相关的转化医学

登录后查看更多信息

100 项与氟尼缩松相关的专利（医药）

登录后查看更多信息

664

项与氟尼缩松相关的文献（医药）

2025-08-01·JOURNAL OF HAZARDOUS MATERIALS

Assessing the chemical burden of the North-East Atlantic ecosystem through targeted and untargeted HRMS-based approaches

Article

作者: Berbee, Rob ; von der Ohe, Peter ; Munch Chistensen, Anne ; Koschorreck, Jan ; Larsen, Martin Mørk ; Mil-Homens, Mário ; Pirntke, Ulrike ; Vasilatos, Konstantinos ; Soerensen, Anne L ; McHugh, Brendan ; Näslund, Johan ; Hjermann, Dag Øystein ; Parmentier, Koen ; Power, Andrew ; Athanasopoulou, Antonia ; Thomaidis, Nikolaos S ; Kammann, Ulrike ; Mauffret, Aourell ; Webster, Lynda ; Wilson, Simon ; Oliveira, Susana Galante ; Alygizakis, Nikiforos ; Burgeot, Thierry ; Oswald, Peter ; Gustafsson, Johan ; Gkotsis, Georgios ; Kirchgeorg, Torben ; Slobodnik, Jaroslav ; Viñas, Lucia ; Campos, Alejandro Iglesias ; Van der Stap, Irene ; Barber, Jonathan L ; Nika, Maria-Christina

Human activities have introduced significant amounts of anthropogenic chemicals into marine ecosystems, posing threats to aquatic biodiversity and human health. Although, traditional marine monitoring focus primarily on legacy pollutants, the presence and potential risks associated with complex emerging chemical mixtures should not be neglected. In the context of the present study organized via OSPAR Commission and supported by NORMAN network, 52 marine samples were gathered from North-East Atlantic Ocean. State-of-the-art HRMS-based analytical workflows were employed to identify their chemical fingerprint. 132 organic pollutants were identified through wide-scope target screening of more than 2,400 environmentally relevant organic pollutants. The HRMS data were digitally stored in NORMAN DSFP and 134 additional chemicals were tentatively identified through suspect screening of more than 65,000 chemicals. The list included legacy pollutants, along with emerging pollutants, their metabolites and transformation products. A simplified environmental risk assessment was conducted, aiming to prioritize substances based on their potential risks to the marine ecosystem. This study provides a valuable snapshot of the marine pollution, offering insights into chemical occurrence and risks. The findings can support marine scientists, environmental managers and policymakers in identifying pollutant sources, understanding their impacts, and informing regulatory measures to mitigate threats to marine ecosystems.

2024-07-16·PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

High-throughput screen identifies non inflammatory small molecule inducers of trained immunity

Article

作者: Chiang, Chun-yi ; Ketter, Ellen ; Chen, Qing ; Weiss, Adam ; Shen, Jingjing ; Barreiro, Luis ; Knight, Hannah Riley ; Ajit, Jainu ; Esser-Kahn, Aaron ; Ip, Ka Man ; Ung, Trevor

Trained immunity is characterized by epigenetic and metabolic reprogramming in response to specific stimuli. This rewiring can result in increased cytokine and effector responses to pathogenic challenges, providing nonspecific protection against disease. It may also improve immune responses to established immunotherapeutics and vaccines. Despite its promise for next-generation therapeutic design, most current understanding and experimentation is conducted with complex and heterogeneous biologically derived molecules, such as β-glucan or the Bacillus Calmette-Guérin (BCG) vaccine. This limited collection of training compounds also limits the study of the genes most involved in training responses as each molecule has both training and nontraining effects. Small molecules with tunable pharmacokinetics and delivery modalities would both assist in the study of trained immunity and its future applications. To identify small molecule inducers of trained immunity, we screened a library of 2,000 drugs and drug-like compounds. Identification of well-defined compounds can improve our understanding of innate immune memory and broaden the scope of its clinical applications. We identified over two dozen small molecules in several chemical classes that induce a training phenotype in the absence of initial immune activation—a current limitation of reported inducers of training. A surprising result was the identification of glucocorticoids, traditionally considered immunosuppressive, providing an unprecedented link between glucocorticoids and trained innate immunity. We chose seven of these top candidates to characterize and establish training activity in vivo. In this work, we expand the number of compounds known to induce trained immunity, creating alternative avenues for studying and applying innate immune training.

2024-07-08·Journal of Chemical Information and Modeling

DrugSK: A Stacked Ensemble Learning Framework for Predicting Drug Combinations of Multiple Diseases

Article

作者: Chen, Siqi ; Li, Kefeng ; Guan, Jibin ; Xiang, Rongwu ; Jiang, Xiwei ; Li, Chunzhi ; Zhai, Fei ; Gao, Nan ; Zhang, Peng ; Ling, Guixia

Combination therapy is an important direction of continuous exploration in the field of medicine, with the core goals of improving treatment efficacy, reducing adverse reactions, and optimizing clinical outcomes. Machine learning technology holds great promise in improving the prediction of drug synergy combinations. However, most studies focus on single disease-oriented collaborative predictive models or involve excessive feature categories, making it challenging to predict the majority of new drugs. To address these challenges, the DrugSK comprehensive model was developed, which utilizes SMILES-BERT to extract structural information from 3492 drugs and trains on reactions from 48,756 drug combinations. DrugSK is an integrated learning model capable of predicting interactions among various drug categories. First, the primary learner is trained from the initial data set. Random forest, support vector machine, and XGboost model are selected as primary learners and logistic regression as secondary learners. A new data set is then "generated" to train level 2 learners, which can be thought of as a prediction for each model. Finally, the results are filtered using logistic regression. Furthermore, the combination of the new antibacterial drug Drafloxacin with other antibacterial agents was tested. The synergistic effect of Drafloxacin and Isavuconazonium in the fight against Candida albicans has been confirmed, providing enlightenment for the clinical treatment of skin infection. DrugSK's prediction is accurate in practical application and can also predict the probability of the outcome. In addition, the tendency of Drafloxacin and antifungal drugs to be synergistic was found. The development of DrugSK will provide a new blueprint for predicting drug combination synergies.

项与氟尼缩松相关的新闻（医药）

2024-04-16

·梅斯医学

春季过敏高峰期来了

春天来临，万物复苏的同时，也带来了一些令人烦恼的问题，其中之一就是过敏，许多人可能会出现打喷嚏、流鼻涕、皮肤瘙痒等过敏症状。过敏是指机体接触致敏物质后出现的变态反应。变态反应又称超敏反应，是机体受同一抗原再次刺激后所发生的一种表现为组织损伤或生理功能紊乱的特异性免疫反应。导致春季过敏高发几个致敏因素1、花粉：春季是植物生长的季节，空气中的花粉含量增加，对于有过敏体质的人群来说，这些花粉可能会引起过敏反应。2、尘螨和霉菌：随着温度和湿度的升高，尘螨和霉菌繁殖加快，它们的存在也可能诱发过敏症状。3、宠物皮屑：宠物的皮屑、毛发和唾液中含有蛋白质，这些蛋白质可能成为过敏原，引起过敏。4、紫外线照射：春季阳光逐渐强烈，紫外线增强，皮肤容易受到损伤，诱发过敏反应。5、气候变化：春季气候变化较大，温度和湿度的波动可能导致皮肤和呼吸道敏感性增加。各类过敏临床表现1、花粉过敏性鼻炎：主要表现为阵发性喷嚏、清水样涕、鼻痒和鼻塞等症状。2、花粉过敏性结膜炎：眼痒，眼睑肿，出现黏液性分泌物。3、花粉过敏性皮疹：皮肤、耳朵等处瘙痒，皮肤出现风疹块、红色斑丘疹、以及湿疹等。4、花粉过敏性哮喘：阵发性咳嗽、呼吸困难，有白色泡沫样黏痰，甚至出现呼吸困难。过敏性鼻炎常用药物治疗1、糖皮质激素（1）鼻用激素：是AR的一线治疗药物，临床推荐使用。鼻用激素分为第一代（包括布地奈德、曲安奈德、丙酸倍氯米松、氟尼缩松）和第二代（包括糠酸莫米松、丙酸氟替卡松、糠酸氟替卡松、倍他米松、环索奈德），与第一代鼻用激素相比，第二代鼻用激素具有高亲脂性、与受体结合力强、抗炎活性更强、生物利用度低等特点。对于轻度AR和中‑重度间歇性AR，疗程不少于2周；对于中‑重度持续性AR是首选药物，疗程4周以上。由于AR存在黏膜最轻炎症持续状态，持续治疗或者最低维持剂量持续治疗对病情的长期控制效果明显优于间断治疗。一般不推荐在妊娠期和哺乳期使用鼻用激素。（2）口服糖皮质激素：是AR的二线治疗药物，临床需要慎重和酌情使用。对于症状严重难以控制的AR可考虑短期口服糖皮质激素。用法用量：剂量按患者体重计算（以泼尼松为例，剂量为0.5~1.0mg/kg），早晨顿服，疗程4~7d。注意全身使用糖皮质激素的不良反应，避免用于儿童、老年人以及有糖皮质激素使用禁忌证的患者。2、抗组胺药（1）口服抗组胺药：第二代抗组胺药为AR的一线治疗药物，可常规用于老年AR患者。这类药物起效快速，作用持续时间较长，能明显缓解鼻部症状特别是鼻痒、喷嚏和流涕，对合并眼部症状也有效，但对改善鼻塞的效果有限。用法用量：一般每天只需用药1次，疗程不少于2周。对花粉过敏的患者，推荐在致敏花粉播散前进行预防性治疗，有利于症状控制，并根据花粉播散时间以及对症状产生的影响而决定疗程。口服抗组胺药罕见发生心脏毒性作用，但应引起重视，临床表现为QT间期延长、尖端扭转型室性心动过速等严重心律失常，如阿司咪唑、特非那定禁止与大环内酯类抗生素、抗真菌药物、人类免疫缺陷病毒蛋白酶抑制剂及其他可潜在引起心律失常类药物合用。部分第二代口服抗组胺药会加重酒精造成的认知和精神运动障碍，所以用药期间需作好患者健康教育。（2）鼻用抗组胺药：是AR的一线治疗药物，其疗效相当于或优于第二代口服抗组胺药，特别是对鼻塞症状的缓解。用法用量：一般每天用药2次，疗程不少于2周。对第二代口服抗组胺药不能有效控制症状的中‑重度季节性AR患者，单独采用氮卓斯汀鼻喷剂治疗2周可明显改善鼻部症状3、肥大细胞膜稳定剂肥大细胞膜稳定剂为AR的二线治疗药物，临床酌情使用。4、减充血剂减充血剂局部应用于鼻腔时，可减轻鼻腔黏膜充血、肿胀状态，迅速缓解鼻塞。减充血剂有两种，第一种为非选择性受体激动的拟交感胺类，包括肾上腺素和麻黄碱等，可以同时兴奋α和β肾上腺素能受体，全身及局部不良反应较明显；第二种为选择性受体激动的半拟交感胺类（咪唑啉衍生物类），包括羟甲唑啉、赛洛唑啉、萘甲唑啉等，是目前常用的鼻腔减充血剂。减充血剂使用不当可致药物性鼻炎。5、抗胆碱能药鼻用抗胆碱能药为AR的二线治疗药物，可控制流涕症状。 6、鼻腔盐水冲洗鼻腔盐水冲洗是一种安全、方便、价廉的治疗方法，通常用于鼻腔和鼻窦炎性疾病的辅助治疗，具有稀释黏液、改善黏液纤毛清除功能、减轻黏膜水肿和减少鼻腔鼻窦中的过敏原负荷等作用。目前在临床使用的鼻腔冲洗装置和方法主要有鼻腔灌洗、喷液和雾化等，冲洗液包括生理盐水、深海盐水和高渗盐水等种类。鼻腔冲洗可作为妊娠期AR的替代疗法。如何预防春季过敏1、避免接触过敏原：过敏体质患者在春季应避免外出，尤其在大风天气时。平时应尽量避免在公园等花草树木较多的环境周围行走。开车时摇上车窗，不在花粉季骑自行车。外出佩戴口罩，必要时要带大一点的墨镜，回到家后要及时用温水清洗裸露皮肤及鼻腔黏膜，将易引起过敏的物质洗干净。此外，对于过敏性皮炎患者，外出要涂防晒霜或者打遮阳伞，做好物理防晒，平时还要减少皮肤洗浴次数，降低皮肤刺激。2、加强体育锻炼：过敏体质患者平时加强运动可选择室内活动，如游泳，室内羽毛球、乒乓球，瑜伽等，适当锻炼可增强身体抵抗力，一定程度上减少过敏的发生。3、注意饮食：平时应注意均衡饮食，避免摄入浓茶、咖啡、海鲜、酒及辛辣刺激性食物，此类食物容易引起过敏反应，长时间大量摄入还可导致身体抵抗力降低，容易导致机体变得敏感。4、其他：平时要注意保持所处环境温度、湿度适宜；避免穿化纤材质的衣服，尽量选择穿棉质柔软宽松的衣服；注意护理好个人卫生，勤洗床单被罩等。撰文 | Anna.An编辑 | Swagpp● 平时熬的夜竟能用周末补上！南京医科大学最新：周末补觉，患心血管疾病风险降70%！但要注意这2点● 震撼！医生质疑：我们院长竟然是文学专业的、书记空降的，外行领导内行，能指望他们做啥？院领导必须临床出身吗？中国院长画像告诉你答案● 重磅！5次问鼎NEJM，吴一龙教授团队或将改写全球指南！ALK阳性NSCLC的辅助治疗显著提高患者生存率版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

2024-03-14

·梅斯医学

花粉过敏高发季又要来了

“草长莺飞二月天，拂堤杨柳醉春烟”。春天，正是山花烂漫之时，孩子们都迫不及待走出家门拥抱春天。可是每当这时候，一些孩子却被“花粉过敏”折磨得苦不堪言，鼻涕喷嚏不断，严重的甚至会出现哮喘症状，呼吸困难。花粉过敏又叫花粉症、枯草热，是一种因吸入外界花粉抗原而引起的过敏性疾病，春季为高发期。花粉过敏是特应性体质患者被花粉致敏后引起的一系列的病理生理过程。花粉过敏为过敏科常见病，且发病率逐年上升，严重影响人类健康。主要表现为呼吸道和结膜的卡他性炎症，可伴有皮肤及其它器官的病变。常见过敏原花粉过敏的“元凶”是花粉，自然界的花粉传播主要分风媒和虫媒两种形式。虫媒花粉，如油菜花、桃花、梨花的花粉，靠蝴蝶或蜜蜂等昆虫传播，特点是花朵鲜艳，带有芳香或其他气味，花粉颗粒较大，花粉量不多，不易四处播散，通常不会引起过敏。风媒花粉，如柏树、杨树、柳树、桦树、梧桐等的花粉，特点是花型小，花粉含量高，质量较轻，可以随风飞到很远的地方，风媒花粉是主要过敏原。临床表现1、花粉过敏性鼻炎：主要表现为阵发性喷嚏、清水样涕、鼻痒和鼻塞等症状。2、花粉过敏性结膜炎：眼痒，眼睑肿，出现黏液性分泌物。3、花粉过敏性皮疹：皮肤、耳朵等处瘙痒，皮肤出现风疹块、红色斑丘疹、以及湿疹等。4、花粉过敏性哮喘：阵发性咳嗽、呼吸困难，有白色泡沫样黏痰，甚至出现呼吸困难。过敏性鼻炎常用药物治疗1、糖皮质激素（1）鼻用激素：是AR的一线治疗药物，临床推荐使用。鼻用激素分为第一代（包括布地奈德、曲安奈德、丙酸倍氯米松、氟尼缩松）和第二代（包括糠酸莫米松、丙酸氟替卡松、糠酸氟替卡松、倍他米松、环索奈德），与第一代鼻用激素相比，第二代鼻用激素具有高亲脂性、与受体结合力强、抗炎活性更强、生物利用度低等特点。对于轻度AR和中‑重度间歇性AR，疗程不少于2周；对于中‑重度持续性AR是首选药物，疗程4周以上。由于AR存在黏膜最轻炎症持续状态，持续治疗或者最低维持剂量持续治疗对病情的长期控制效果明显优于间断治疗。一般不推荐在妊娠期和哺乳期使用鼻用激素。（2）口服糖皮质激素：是AR的二线治疗药物，临床需要慎重和酌情使用。对于症状严重难以控制的AR可考虑短期口服糖皮质激素。用法用量：剂量按患者体重计算（以泼尼松为例，剂量为0.5~1.0mg/kg），早晨顿服，疗程4~7d。注意全身使用糖皮质激素的不良反应，避免用于儿童、老年人以及有糖皮质激素使用禁忌证的患者。2、抗组胺药（1）口服抗组胺药：第二代抗组胺药为AR的一线治疗药物，可常规用于老年AR患者。这类药物起效快速，作用持续时间较长，能明显缓解鼻部症状特别是鼻痒、喷嚏和流涕，对合并眼部症状也有效，但对改善鼻塞的效果有限。用法用量：一般每天只需用药1次，疗程不少于2周。对花粉过敏的患者，推荐在致敏花粉播散前进行预防性治疗，有利于症状控制，并根据花粉播散时间以及对症状产生的影响而决定疗程。口服抗组胺药罕见发生心脏毒性作用，但应引起重视，临床表现为QT间期延长、尖端扭转型室性心动过速等严重心律失常，如阿司咪唑、特非那定禁止与大环内酯类抗生素、抗真菌药物、人类免疫缺陷病毒蛋白酶抑制剂及其他可潜在引起心律失常类药物合用。部分第二代口服抗组胺药会加重酒精造成的认知和精神运动障碍，所以用药期间需作好患者健康教育。（2）鼻用抗组胺药：是AR的一线治疗药物，其疗效相当于或优于第二代口服抗组胺药，特别是对鼻塞症状的缓解。用法用量：一般每天用药2次，疗程不少于2周。对第二代口服抗组胺药不能有效控制症状的中‑重度季节性AR患者，单独采用氮卓斯汀鼻喷剂治疗2周可明显改善鼻部症状3、肥大细胞膜稳定剂肥大细胞膜稳定剂为AR的二线治疗药物，临床酌情使用。4、减充血剂减充血剂局部应用于鼻腔时，可减轻鼻腔黏膜充血、肿胀状态，迅速缓解鼻塞。减充血剂有两种，第一种为非选择性受体激动的拟交感胺类，包括肾上腺素和麻黄碱等，可以同时兴奋α和β肾上腺素能受体，全身及局部不良反应较明显；第二种为选择性受体激动的半拟交感胺类（咪唑啉衍生物类），包括羟甲唑啉、赛洛唑啉、萘甲唑啉等，是目前常用的鼻腔减充血剂。减充血剂使用不当可致药物性鼻炎。5、抗胆碱能药鼻用抗胆碱能药为AR的二线治疗药物，可控制流涕症状。6、鼻腔盐水冲洗鼻腔盐水冲洗是一种安全、方便、价廉的治疗方法，通常用于鼻腔和鼻窦炎性疾病的辅助治疗，具有稀释黏液、改善黏液纤毛清除功能、减轻黏膜水肿和减少鼻腔鼻窦中的过敏原负荷等作用。目前在临床使用的鼻腔冲洗装置和方法主要有鼻腔灌洗、喷液和雾化等，冲洗液包括生理盐水、深海盐水和高渗盐水等种类。鼻腔冲洗可作为妊娠期AR的替代疗法。参考文献：中国变应性鼻炎诊断和治疗指南（2022版）撰文 | Anna.An编辑 | Swagpp● 接种217针新冠疫苗，身体会发生什么？柳叶刀：全球接种最多的“免疫系统竟一切正常！● 远离女性，寿命更长？最新研究：只要感知到雌性的气味，就会增加雄性的死亡率以及生殖衰老● 泪目！一25岁专硕规培生，在医院内割颈自杀！遗书疑曝光：我好累，熬不下去了，这个世界再也不见！血泪教训，规培生绝不能是廉价劳动力版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

100 项与氟尼缩松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00324	氟尼缩松	R01AD04 R03BA03	DB00180

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
哮喘	美国	Roche Palo Alto LLC	1984-08-17
常年性变应性鼻炎	美国	Ivax Research, Inc.	1981-09-24
季节性过敏性鼻炎	美国	Ivax Research, Inc.	1981-09-24

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
气道病变	临床阶段不明	美国	Meda Pharmaceuticals, Inc.	2015-03-01
儿童哮喘	临床阶段不明	美国	Meda Pharmaceuticals, Inc.	2015-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02404103 (CTgov)	N/A	气道病变 \| 儿童哮喘	26	Flunisolide HFA (Flunisolide 160 mcg Per Day)	選膚鹹糧鬱廠蓋艱獵遞(願憲壓鏇築鑰膚夢築築) = 蓋鹹襯廠顧壓願衊壓廠網襯構鬱遞廠鬱鑰製艱 (願齋簾顧網願憲繭製艱, 範醖簾蓋餘蓋築淵壓壓 ~ 鹹糧選餘醖憲壓廠蓋憲) 更多	-	2017-10-20
				Flunisolide HFA (Flunisolide 320 mcg Per Day)	選膚鹹糧鬱廠蓋艱獵遞(願憲壓鏇築鑰膚夢築築) = 淵觸蓋觸鑰製鏇築窪遞網襯構鬱遞廠鬱鑰製艱 (願齋簾顧網願憲繭製艱, 顧鹽衊遞夢餘窪廠鏇築 ~ 顧艱齋窪鏇積衊積積觸) 更多
ACAAI2016	N/A	-	4	Flunisolide 80μg (Meda)	鏇遞襯構鏇壓膚鬱製顧(選鏇簾願觸積積繭衊壓) = 壓餘築夢廠選蓋艱範製築積壓醖餘鏇鑰糧願衊 (顧淵窪糧鏇齋醖鏇廠窪 ) 更多	-	2016-11-10
				Fluticasone 110μg (GSK)	鏇遞襯構鏇壓膚鬱製顧(選鏇簾願觸積積繭衊壓) = 築鏇齋範壓觸蓋選鑰餘築積壓醖餘鏇鑰糧願衊 (顧淵窪糧鏇齋醖鏇廠窪 ) 更多
AAAAI2016	N/A	中度哮喘	-	Flunisolide HFA	鑰齋構鹹構窪艱蓋廠醖(鹹醖餘糧觸構夢醖膚製) = 鹽衊糧築願糧願網願蓋壓廠夢獵醖膚構餘淵選 (衊齋壓網遞構築獵壓鬱 )	-	2016-02-01
				Placebo	鑰齋構鹹構窪艱蓋廠醖(鹹醖餘糧觸構夢醖膚製) = 簾齋壓願鬱餘繭觸鑰憲壓廠夢獵醖膚構餘淵選 (衊齋壓網遞構築獵壓鬱 )
AAAAI2015	N/A	-	513	Flunisolide HFA 80 mcg	遞餘淵淵襯築夢艱構積(糧製觸餘繭餘壓選淵願) = 餘餘膚衊糧鏇廠衊網繭繭構蓋憲遞鹹鹽衊繭齋 (遞簾築糧願鹹壓願簾構 )	-	2015-02-01
				Flunisolide HFA 160 mcg	遞餘淵淵襯築夢艱構積(糧製觸餘繭餘壓選淵願) = 繭壓壓憲夢鬱選遞憲膚繭構蓋憲遞鹹鹽衊繭齋 (遞簾築糧願鹹壓願簾構 )
AAAAI2005	N/A	-	-	Fluticasone propionate (FP)	鑰鹽鑰願繭範繭獵窪製(淵蓋膚醖餘繭簾願簾糧) = 鏇廠繭構壓構鏇繭範淵遞淵壓簾簾艱鹹願願糧 (範築窪鏇顧範壓廠構製, 0.48)	-	2005-03-19
				Des-ciclesonide (des-CIC)	鑰鹽鑰願繭範繭獵窪製(淵蓋膚醖餘繭簾願簾糧) = 鑰構築膚遞鹹範鬱襯範遞淵壓簾簾艱鹹願願糧 (範築窪鏇顧範壓廠構製, 0.3)